Psychiatr. pro Praxi, 2006; 5: 211-213

Osteoporosis and schizophrenia

MUDr. Ivan Tůma CSc
Psychiatrická klinika LF UK a FN Hradec Králové

Osteoporosis is a multifactorial disease. Untreated patients with schizophrenia are at risk due to the consequences of the disease related lifestyle factors (nutritional alteration, smoking, polydipsia, lack of physical activity). The etiology of the osteoporosis may be partly explained by the prolacting-raising effect of antipsychotic medication. Hyperprolactinemia itself does not lead to osteoporosis. Decrease of bone mineral density associated with schizophrenia may result from hypogonadism secondary to antipsychotic-induced hyperprolactinemia. The most common clinical signs of hypogonadism is dys/amenorrhea, and galactorrhea in female patients, and sexual dysfunction or gynekomasty in male patients. The prolacting-raising profile of antipsychotic drugs should be considered in treatment plans. Reduction of nicotin abuse and physical activities decrease the risk of osteoporosis in schizophrenic patients.

Keywords: osteoporosis, bone mineral density, schizophrenia, antipsychotics, prolactin

Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tůma I. Osteoporosis and schizophrenia. Psychiatr. praxi. 2006;7(5):211-213.
Download citation

References

  1. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003; 64: 761-766. Go to original source... Go to PubMed...
  2. Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M, Tan U. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002; 112 (7): 817-828. Go to original source... Go to PubMed...
  3. Delva NJ, Crammer JL, Jarzylo SV, Lawson JS, Owen JA, Sribney M, Weir BJ, Yendt ER. Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol Psychiatry1989; 26 (8): 781-93. Go to original source... Go to PubMed...
  4. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982; 170 (8): 463-7. Go to original source... Go to PubMed...
  5. Hála T. Rizikové faktory osteoporózy. Medicína pro praxi 2005; 4: 152-154.
  6. Hummer M, Malik P, Gasser RW, Hofer A, Kemmler G, Naveda RCM, Rettenbacher MA, Fleischhacker WW. Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005; 162: 162-167. Go to original source... Go to PubMed...
  7. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003; 28 Suppl 2: 69-82. Go to original source... Go to PubMed...
  8. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992; 19 (9): 603-6. Go to original source... Go to PubMed...
  9. Lehman D, Meyer JM. Decreased bone mineral density in male schizophrenia patients. Schizophr Res 2000; 46 (2-3): 131-133. Go to original source... Go to PubMed...
  10. Meyer JM, Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry 2006; 18 (1): 43-48. Go to original source... Go to PubMed...
  11. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolismus. J Clin Psychiatry 65; 12: 1607-1618. Go to original source... Go to PubMed...
  12. Mohr P, Horacek J, Motlova L, Libiger J, Czobor P. Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. Psychopharmacology (Berl) 1999; 141 (3): 322-5. Go to original source... Go to PubMed...
  13. Naidoo U, Goff DC, Klabinski A. Hyperprolaktinemia and bone density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28: 97-108. Go to original source... Go to PubMed...
  14. Palička V. Osteologie. In Bureš J, Horáček J (Eds) Základy vnitřního lékařství. Galén 2003: 870.
  15. Szarfman A, Tonning JM, Levin JG, Doraiswamy PM. Atypical antipsychotic and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006 June; 26 (6): 748-58. Go to original source... Go to PubMed...
  16. Wyszogrodzka-Kucharska A, Rabe-Jablonska J. Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics. Psychiatr Pol 2005; 39: 1173-1184. Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.